GPT and metabolic dysfunction-associated steatotic liver disease: Inoue and coworkers demonstrated that canagliflozin (100 mg/day) significantly improved LFT levels (AST, ALT, and GGT) in T2DM patients with NAFLD (Inoue et al., 2019[40]).